CAMBRIDGE, Mass. - s4story -- EyeCool Therapeutics today announced the publication of a prospective study evaluating its investigational ophthalmic cooling device, ETX-4143, for the treatment of chronic ocular surface pain (COSP). The positive findings further support the development of precision ocular cooling as a potential new therapeutic category for chronic ocular surface pain, demonstrating that a single in-office treatment was associated with significant reductions in ocular pain for up to 12 weeks while preserving corneal nerve morphology and ocular surface health.

The study, "Impact of an Ophthalmic Cooling Device on Corneal Immune and Sensory Nerve Features in Chronic Ocular Surface Pain: A Prospective, Feasibility Study," evaluated the safety and biological effects of ETX-4143 in adults with chronic ocular surface pain. In this prospective paired-eye feasibility study, five participants received a single 4-minute treatment in their more symptomatic eye using the investigational cooling device, while the fellow eye served as an untreated control. Participants were followed for 12 weeks with comprehensive clinical assessments and advanced corneal in vivo confocal microscopy. See full research paper (https://link.springer.com/article/10.1007/s40123-026-01454-6).

More on S For Story

• CCHR: Congressional Hearing Revives Lessons from MKULTRA Era – Why Past Psychiatric Human Rights Abuses Demand Vigilance Today
• Pacto Medical Wins Red Dot Design Concept Award 2026 for Slimshot® Compact Prefilled Syringe
• Don't Miss Your Chance to Be Part of History!
• Heritage at Manalapan Introduces Luxury Single-Family Homes with Exceptional Value in One of Monmouth County's Most Desirable Locations
• Achugogo: Tale of the Spring Chaser Wins Inaugural TCCF Prize at Mifa Pitches, the Industry Market of the Annecy International Animation Film Festival

Relative to baseline, ocular pain severity was significantly reduced at 2, 6, and 12 weeks following treatment, with maintained effect over time. Clinical assessments demonstrated that visual acuity, tear osmolarity, corneal sensitivity, ocular surface integrity, and corneal nerve morphology remained stable throughout the study, supporting the favorable safety profile of ETX-4143.

Notably, use of the advanced functional in vivo confocal microscopy (Fun-IVCM) technique for exploratory endpoints revealed changes in corneal immune cell behavior following treatment. Investigators observed increased motility of putative intraepithelial T cells during the early post-treatment period, followed by reductions in both T-cell motility and dendritic cell probing behavior at 12 weeks. These findings suggest that localized cooling adjacent to the cornea may influence corneal immune dynamics, although the authors note that these observations are only exploratory and hypothesis-generating at this point.

The study concluded that, within this participant cohort, ETX-4143 had indicators of a favorable safety profile while improving pain outcomes and modulating corneal immune dynamics through 12 weeks after treatment. The authors noted that larger, randomized controlled trials are warranted to further evaluate the clinical efficacy, durability, and mechanisms of treatment.

More on S For Story

• "Images in Green" by Edward Forde Hickey is published
• Everything Policy Launches Madison, an AI Tool That Makes Legislation Readable for Students and Citizens
• Stirring Events Accompany Audiobook Creator's Pursuit of an Audie Award
• Is the Market Missing One of the Most Undervalued Cybersecurity Companies on the Stock Market? Cycurion, Inc. (N A S D A Q: CYCU):
• Billion-Dollar Scale Global Technology Powerhouse Being Built with Expanding Government Contracts: Circle8 Group (N A S D A Q: CIRC)

Together, these findings strengthen the scientific rationale for precision ocular cooling as a distinct therapeutic approach for chronic ocular surface pain, a condition for which there are currently no FDA-approved treatments.

About EyeCool Therapeutics Inc.

EyeCool Therapeutics is a clinical-stage medical device company pioneering precision ocular cooling as a potential new therapeutic category for chronic ocular surface pain.

Important Safety Information

Warning: This product has not been approved or cleared for marketing by the U.S. Food and Drug Administration and is considered an investigational device. For more info, please visit www.eyecooltx.com.